{"id":"NCT00839527","sponsor":"GlaxoSmithKline","briefTitle":"A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes","officialTitle":"A Randomized, Double-blind, Placebo and Active-Controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination With Metformin and Glimepiride Compared With Metformin Plus Glimepiride and Placebo and With Metformin Plus Glimepiride and Pioglitazone in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-02","primaryCompletion":"2012-01","completion":"2013-04","firstPosted":"2009-02-09","resultsPosted":"2014-07-01","lastUpdate":"2017-01-09"},"enrollment":685,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"placebo to match albiglutide","otherNames":[]},{"type":"BIOLOGICAL","name":"albiglutide","otherNames":[]},{"type":"DRUG","name":"metformin","otherNames":[]},{"type":"DRUG","name":"glimepiride","otherNames":[]},{"type":"DRUG","name":"pioglitazone","otherNames":[]},{"type":"DRUG","name":"placebo to match pioglitazone","otherNames":[]}],"arms":[{"label":"metformin + glimepiride + pioglitazone + albiglutide placebo","type":"ACTIVE_COMPARATOR"},{"label":"metformin + glimepiride + pioglitazone placebo + albiglutide","type":"EXPERIMENTAL"},{"label":"met + glimepiride + pioglitazone placebo + albiglutide placebo","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes","primaryOutcome":{"measure":"Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52","timeFrame":"Baseline and Week 52","effectByArm":[{"arm":"Placebo + Metformin + Glimepiride","deltaMin":0.33,"sd":0.083},{"arm":"Pioglitazone + Metformin + Glimepiride","deltaMin":-0.8,"sd":0.055},{"arm":"Albiglutide + Metformin + Glimepiride","deltaMin":-0.55,"sd":0.055}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"0.2685"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":358,"countries":["United States","Germany","Hong Kong","India","Peru","Philippines","Russia","Spain","United Kingdom"]},"refs":{"pmids":["28683300","25387217","24918790"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":115},"commonTop":["Hypoglycaemia","Upper respiratory tract infection","Nasopharyngitis","Diarrhoea","Urinary tract infection"]}}